ORCL - Oracle has to show it can execute with Cerner deal Monness Crespi Hardt says

Oracle's (NYSE:ORCL) decision to acquire Cerner (NASDAQ:CERN) for $95 per share in cash could wind up being "disruptive," Monness Crespi Hardt analyst Brian White wrote in a note to investors, while adding that it could also help the Larry Ellison-founded company help transform healthcare. In a note to investors, White, who rates Oracle (ORCL) buy with a $126 price target, said that he is "leery of large acquisitions," as they don't often deliver the expected cost savings and fall short of financial expectations, while being disruptive to the company's core business. However, Cerner (CERN), which provides electronic medical records, can help Oracle (ORCL) further expand into the healthcare space, especially since it is still early in its "digital transformation journey." "We believe Oracle offers investors a high-quality, value play with the opportunity to capitalize on the company’s cloud transformation and increasingly attractive model," White wrote in a note to investors.

For further details see:

Oracle has to show it can execute with Cerner deal, Monness Crespi Hardt says